Although the overactivity of CB1R was found contributing to the pathogenesis of pulmonary fibrosis, the pharmaceutical development of CB1R antagonist and their potential therapeutic uses in fibrosis was halted (Cinar et al., 2016). The gene discussed is CNR1; the disease is pulmonary fibrosis.